Castleview Partners’s Innoviva INVA Stock Holding History

Castleview Partners’s Portfolio INVA Stock Details INVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-23	Closed	-$304	–	690
2022 Q4	$304	Buy	+23	New	+$302	﹤0.01%	601

Other funds holding INVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Castleview Partners's INVA Position: Q1 2023 in Review

Castleview Partners sold out of Innoviva (INVA) in Q1 2023, closing a stake of 23 shares — an estimated $304 sold.

Castleview Partners first reported a position in INVA in Q4 2022 and held it in 1 quarter. The position peaked at $304 in Q4 2022. 193 funds tracked by Wall St. Rank hold INVA as of Q1 2023.

Castleview Partners reported no remaining Innoviva position as of Q1 2023 after selling out during the quarter.
Castleview Partners sold 23 Innoviva shares in Q1 2023, an estimated $304.
Castleview Partners first reported a position in Innoviva in Q4 2022 and held it in 1 quarter.
Castleview Partners's Innoviva position peaked at $304 in Q4 2022.
193 funds tracked by Wall St. Rank held Innoviva as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.